A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis

Author： Gottlieb Alice B.   Cooper Kevin D.   McCormick Thomas S.   Toichi Eiko   Everitt Daniel E.   Frederick Bart   Zhu Yaowei   Pendley Charles E.   Graham Martin A.   Mascelli Mary Ann  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.23, Iss.5, 2007-05, pp. : 1081-1092

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase 1, placebo-controlled, randomised, double-blind (within dose panels) study evaluating the safety, tolerability and pharmacokinetics of intravenous NXY-059 in Japanese subjects

By Watabe Mitsuo   Cheng Yi-Fang   Nilsson Dag   Itoh Yohji   Kumagai Yuji  

Current Medical Research and Opinion, Vol. 23, Iss. 8, 2007-08 ,pp. : 1849-1857

Informa Healthcare

Access to resources Recommend Favorite

Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalating Phase I, Healthy Subjects Study of Intravenous OPN‐305, a Humanized Anti‐TLR2 Antibody

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 94, Iss. 5, 2013-11 ,pp. : 593-600

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tildrakizumab (MK‐3222), an anti‐interleukin‐23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo‐controlled trial

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 173, Iss. 4, 2015-10 ,pp. : 930-939

John Wiley & Sons Inc

Access to resources Recommend Favorite

Acute cardiovascular effects of bitter orange extract (p‐synephrine) consumed alone and in combination with caffeine in human subjects: A placebo‐controlled, double‐blind study

By  

PHYTOTHERAPY RESEARCH, Vol. 32, Iss. 1, 2018-01 ,pp. : 94-102

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase 2a randomized, double‐blind, placebo‐controlled, sequential dose‐escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate‐to‐severe psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 173, Iss. 3, 2015-09 ,pp. : 767-776

John Wiley & Sons Inc

Access to resources Recommend Favorite